Phase 2 Study of MLN0128 Combination of MLN0128 With MLN1117 Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer

    Not Recruiting
  • participants needed
  • sponsor
    Millennium Pharmaceuticals, Inc.
Updated on 1 December 2021
ct scan
platelet count
measurable disease
maintenance therapy
neutrophil count
solid tumour
hemoglobin a1c
endometrial carcinoma


The primary purpose of this study is to determine if MLN0128 in combination with weekly paclitaxel improves progression-free survival (PFS) compared to weekly paclitaxel alone.


The drugs being evaluated in this study are MLN0128 and MLN1117. MLN0128 is being evaluated as a single agent and in combination with paclitaxel or MLN1117 to treat women with advanced, recurrent, or persistent endometrial cancer. This study will evaluate the efficacy and safety of each drug or drug combination.

The study will enroll approximately 242 participants. Participants will be randomly assigned (by chance, like flipping a coin) to one of 4 treatment groups:

  • Paclitaxel 80 mg/m^2 weekly
  • Paclitaxel 80 mg/m^2 weekly + MLN0128 4 mg 3 consecutive days each week
  • MLN0128 30 mg weekly
  • MLN0128 4 mg + MLN1117 200 mg both given 3 consecutive days each week

Participants will receive either Paclitaxel intravenous (IV) weekly, Paclitaxel IV along with MLN0128 orally, MLN0128 orally, or MLN0128 and MLN1117 orally.

This is a multicenter, multinational trial. Participants will make multiple visits to the clinic, with an end of treatment visit (EOT) which will occur 30 to 40 days after receiving their last dose of study drug or before the start of any subsequent anticancer therapy. After EOT, participants will be followed for PFS and overall survival (OS).

Condition Endometrial Carcinoma
Treatment Paclitaxel, MLN0128, MLN1117
Clinical Study IdentifierNCT02725268
SponsorMillennium Pharmaceuticals, Inc.
Last Modified on1 December 2021

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note